Sutro Biopharma, Inc.
STRO · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $102M | $62.0M | +65.2% |
| Operating income | −$158M | −$238M | +33.6% |
| Net income | −$191M | −$227M | +16.0% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 12, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $9.10M | $9.70M | −6.2% |
| Operating income | −$22.0M | −$48.5M | +54.6% |
| Net income | −$31.5M | −$56.9M | +44.6% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Sutro Biopharma's revenue in FY2025?
- $102M in FY2025 (Fiscal year ended Dec 31, 2025), +65.2% vs $62.0M a year earlier, per its 10-K filed Mar 2026.
- Was Sutro Biopharma profitable in FY2025?
- No: net income was −$191M and operating income −$158M in FY2025.
- What was Sutro Biopharma's revenue in Q3 2026?
- $9.10M (−6.2% vs a year earlier), per its Form 10-Q filed Nov 12, 2026.